Information Provided By:
Fly News Breaks for September 23, 2016
NBIX, TEVA
Sep 23, 2016 | 07:56 EDT
Leerink analyst Jason Gerberry says the AIM-TD study readout clinically de-risks Teva's (TEVA) SD-809 opportunity for tardive dyskinesia, with the investor focus shifting to market size and competitive differentiation versus Neurocrine's (NBIX) valbenazine. The analyst believes Teva's SD-809 is well positioned to compete against valbenazine with an equally efficacious and well tolerated drug. Further, he expects Teva to exit 2017 with a broader label. Gerberry reiterates an Outperform rating on Teva's shares.
News For TEVA;NBIX From the Last 2 Days
NBIX
NBIX
NBIX
NBIX
NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.